The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Thrombolytic Therapy

Thrombolytic Therapy

Thrombolytic Therapy is a medical intervention that utilizes pharmacological agents to dissolve or break up blood clots (thrombi) within the body.
This treatment approach is commonly used in the management of conditions such as acute myocardial infarction, ischemic stroke, and deep vein thrombosis.
The goal of Thrombolytic Therapy is to restore blood flow and prevent further tissue damage caused by the obstructed blood vessel.
Effecttive protocols for this therapy are crucial for ensuring optimal outcomes and reproducibility in clinical research and practice.

Most cited protocols related to «Thrombolytic Therapy»

Patients who were at least 18 years of age were enrolled if they could undergo randomization within 12 hours after having an acute ischemic stroke with a score of 3 or less on the National Institutes of Health Stroke Scale (NIHSS) (scores range from 0 to 42, with higher scores indicating greater stroke severity) or a high-risk TIA with a score of 4 or more on the ABCD2 (link) scale14 (which estimates the risk of recurrent stroke after a TIA on the basis of age, blood pressure, clinical features, duration of symptoms, and presence of diabetes; scores ranges from 0 to 7, with higher scores indicating a greater risk of stroke). They were also required to undergo computed tomography or magnetic resonance imaging to rule out intracranial bleeding or other conditions that could explain the neurologic symptoms or detect any contraindications to a trial treatment. Patients with TIA and minor, nondisabling ischemic stroke are generally not considered to be candidates for thrombolysis or endovascular therapy.10 (link) Additional details regarding the inclusion and exclusion criteria are provided in the protocol.13 (link)Patients were ineligible if the symptoms of the initial TIA were limited to isolated numbness, isolated visual changes, or isolated dizziness or vertigo or if they had received any thrombolytic therapy within 1 week before the event. Patients were also ineligible if they were candidates for thrombolysis, endovascular therapy, or endarterectomy; had planned use of antiplatelet therapy or anticoagulation therapy (including those with presumed atrial fibrillation or cardiovascular disease, in whom anticoagulation would be indicated); had a contraindication to aspirin or clopidogrel; or had anticipated use of a nonsteroidal antiinflammatory drug for more than 7 days during the trial period. Written informed consent was required before the performance of any trial procedure.
Publication 2018
Acute Ischemic Stroke Anti-Inflammatory Agents, Non-Steroidal Aspirin Atrial Fibrillation Blood Pressure Cardiovascular Diseases Cerebrovascular Accident Clopidogrel Diabetes Mellitus Endarterectomy Fibrinolytic Agents Neurologic Symptoms Patients Stroke, Ischemic Therapeutics Thrombolytic Therapy Vertigo X-Ray Computed Tomography
Attributes considered in designing a registry must ensure that data are valid, reliable, responsive, interpretable, and translatable
[37 ]. UTHSR is a prospective registry initially designed to capture essential information on all patients admitted to the UTHealth in-patient stroke service at MHH-TMC, with the primary aims of tracking the number of patients treated with intravenous (IV) tPA, their essential demographics, and complication rates, and to support research by members of the stroke team. With the funding of SPOTRIAS, the Principal Investigators (PIs) of the original SPOTRIAS sites decided to obtain common data elements that described essential demographics of all patients treated with IV tPA or enrolled in any clinical trials. UTHSR was consequently expanded to incorporate other elements including those variables that were needed for clinical trials that were conducted by the UT stroke team and variables that were needed for reporting to The Joint Commission (TJC)
[38 ,39 (link)], as well as select variables to meet minimum requirements for reporting to Centers for Medicare and Medicaid Services (CMS) as they pertain to the vascular neurology aspects of required reporting
[40 ]. All patients who have been admitted to the stroke unit at MHH-TMC are classified by stroke diagnosis subtypes, including infarct (non-hemorrhagic stroke), intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), transient ischemic attack (TIA), subarachnoid hemorrhage (SAH), epidural hematomas (EDH), subdural hematomas (SDH), non-acute infarct, and others that could not be classified as any of the above (“Not stroke”), and are entered in UTHSR. Other data elements include admission information (e.g., arrival date and time), medical history, National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) score, Glasgow Coma Scale (GCS), laboratory results, CT scan, CT scan angiogram, MRI, MR angiogram images, thrombolysis therapy (e.g., tPA time and door to needle time), intra-arterial therapy (IAT), complications, and discharge information including: death, mRS on discharge (or day 7, whichever comes first), discharge disposition (home, skilled nursing facility, etc.), and particularly patient education and mRS at 90 days. Currently, the UTHealth stroke team captures up to 235 variables for each patient depending on stroke subtypes. Since some of these variables have multiple responses (e.g., medical history), the number of fields in UTHSR is 372. As UTHSR is modified, corresponding changes to the codebook are made; the codebook is also updated periodically as changes to the abstraction rules are identified or where clarity can be improved. The data core has developed policies for documentation. Members of the data core are responsible for adhering to all policies and procedures established.
Publication 2013
Angiography Arteries Blood Vessel Cerebral Hemorrhage Cerebrovascular Accident Diagnosis Education of Patients Hematoma, Epidural, Cranial Hematoma, Subdural Hemorrhage Hemorrhagic Stroke Infarction Joints Needles Patient Discharge Patients Subarachnoid Hemorrhage Therapeutics Thrombolytic Therapy Transient Ischemic Attack X-Ray Computed Tomography
The project started with development of an 8-question survey tool (online Appendix A) via a multi-disciplinary expert consensus process. Four pairs of questions focused on the following attributes: EMS devices and destination protocols, the designation of certain percutaneous coronary intervention (PCI) hospitals as STEMI Receiving Centers (SRC), inter-hospital transfer protocols for non-PCI Referral Hospitals, and the region’s quality improvement (QI) process. The degree of utilization for each variable was assessed by a multiple-choice format for each LEMSA region: A- none (0%), B- some (<50%), C-most (50–94%), D- all (≥95%), and E- unknown. The duration was evaluated by asking participants for the calendar year that choice C or D was true for each of the eight questions.
Next, the 8-question survey tool was distributed at the annual meeting of administrators and medical directors of California LEMSAs to get responses valid through December, 2014. Incomplete or inconsistent survey response received email follow-up for clarification by the study coordinator. Published ranking will be de-identified, but each LEMSA will confidentially receive their scores.
The first scoring approach was the Total Regionalization Score (TRS). Points were assigned for each selected answer in the survey (A = 0 points, B = 1 point, C = 2 points, D = 3 points) and multiplied by the number of years that each choice was True. This calculation was repeated for all eight questions in the survey and summed to yield the TRS for each LEMSA. The 33 LEMSAs were then ranked from highest to lowest TRS on an Excel spreadsheet.
An example of TRS calculations comes from a hypothetical region that first equipped at least 50% of its paramedic units with PH-ECG devices in the year 2010, and then was able to equip all their ambulances in 2011. Thus, the “C” choice in 2010 would equal 2 points (2 points × 1 year) and a “D” choice from 2011–2014 would equal 12 points (3 points × 4 years), resulting in 14 total points for Question #1. Repeat these steps for Questions #2 to #8 and sum to find the TRS for this hypothetical LEMSA.
The second approach was called the Core Score, and it focused on only 4 survey questions by assuming that the designation of STEMI Receiving Centers must have occurred at the beginning of any LEMSA’s regionalization effort. The Core Score then evaluated the evolution of either pre-hospital or inter-hospital networks as a spectrum: None, Partial, Substantial, or Complete and scored as 0, 1, 2, and 3 points, respectively, for each year that a given threshold was achieved. Core elements of any pre-hospital (PH) network are the presence of PH-ECG devices and Destination Protocols to the SRC (survey Questions 1 and 2). Similarly, inter-hospital transfer primarily depends on identifying the two types of non-PCI hospitals: Type 1 Referral Hospitals are urban/suburban and transfer directly to an SRC for primary PCI (Question 5), whereas Type 2 Referral Hospitals are too far away (rural/remote) to meet guideline-based PCI metrics and need to provide pre-transfer Fibrinolytics to eligible patients (Question 6).
With the Core Score, partial regionalization was defined as the occurrence of “C” status for either pre-hospital (both Questions #1 and #2) or inter-hospital survey items (either Questions #5 or #6), whereas Substantial regionalization occurred in the calendar year that “C” applied for both pre-hospital and inter-hospital questions. Complete regionalization in LEMSA occurred in the calendar year that “D” (≥95%) was selected both for Questions #1 and #2, as well as the highest choice from either Question #5 or #6.
A Core Score calculation example comes from the following hypothetical region. In 2008, this region equipped more than 50% of the ambulances with PH-ECG devices and simultaneously instituted destination protocols. Next, in 2010, it got most Referral hospitals transferring to their nearest SRC, and then in 2012 got all (≥95%) of the EMS vehicles fully equipped and all of their Referral Hospitals transferring. This scenario would be quantified as follows: Two years (2008–09) of Partial regionalization would yield 2 points, two years (2010–2011) of Substantial regionalization would yield 4 points, and three years (2012–2014) of Complete regionalization would yield 9 points, for a total Core Score of 15 points.
Publication 2016
Administrators Ambulances Biological Evolution Hospital Referral Medical Devices Paramedical Personnel Patient Transfer Percutaneous Coronary Intervention Physician Executives ST Segment Elevation Myocardial Infarction Thrombolytic Therapy
Discharge with ischemic stroke (IS), ICH (including non-traumatic subdural hematoma), and SAH were identified with KCD codes I63, I61-2, and I60, respectively. Use of intravenous thrombolysis (IVT) was identified with the drug code for rtPA since there is no procedure code for IVT in the Korean NHI claims data. IAT was identified using the procedure codes for percutaneous thrombolysis for the intracranial artery, percutaneous thrombolysis for other artery, and mechanical or aspiration thrombectomy (M6631, M6632, and M6633, respectively). The following European Cooperative Acute Stroke Study III criteria were used to detect symptomatic intracranial hemorrhage (SICH) following thrombolytic therapy: any apparently extravascular blood in the brain or within the cranium associated with a worsening of the National Institutes of Health Stroke Scale score of ≥4 or leading to death.18 (link)
Reviews of medical records and brain imaging or prospective stroke registry were considered the gold standards. In this study, stroke was defined as an acute neurological deficit caused by focal cerebral ischemia, brain parenchymal hemorrhage, or bleeding into the subarachnoid space.19 (link) Admissions with acute stroke were identified by limiting admissions to within 4 weeks of symptom onset. Three algorithms for stroke diagnoses were tested: 1) all available diagnoses up to nine positions, 2) one primary diagnosis and one secondary diagnosis, and 3) only one primary diagnosis. The sensitivity, specificity, positive predictive value (PPV), and agreement were calculated for each algorithm using a 2×2 table [hospital discharge data diagnosis (yes/no) versus gold standard diagnosis (yes/no)]. Finally, overall agreement was computed using all stroke subtypes (4×4 table) together for a given algorithm. The accuracies among different hospital departments were examined by performing the same analysis by discharge department. The degree of agreement, κ, was defined as substantial (0.61≤κ≤0.80) or almost perfect (0.81≤κ≤1.00).20 (link)
Publication 2015
Acute Cerebrovascular Accidents Alteplase Arteries Aspiration Thrombectomy BLOOD Brain Cerebral Ischemia Cerebrovascular Accident Cranium Diagnosis Europeans Fibrinolytic Agents Gold Hemorrhage, Brain Hypersensitivity Intracranial Hemorrhage Koreans Patient Discharge Pharmaceutical Preparations Stroke, Ischemic Subarachnoid Space Subdural Hematoma, Traumatic Thrombolytic Therapy

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
BLOOD Healthy Volunteers Homo sapiens Phosphates Saline Solution Serum Albumin, Bovine Thrombolytic Therapy

Most recents protocols related to «Thrombolytic Therapy»

Study type: published Observational study;
Subjects: patients diagnosed with ACI according to the diagnostic criteria of the Cerebrovascular Group, Chinese Society of Neurology, Chinese medical association, and the American heart association/American stroke association.[19 ,20 (link)] There were no restrictions on age, gender, or the source of medical records for the study subjects;
Intervention measures: the treatment group was treated with NBP injection alone or in combination with conventional treatment with Western medicine or thrombolytic therapy;
The control group received only conventional treatment with Western medicine or thrombolytic therapy;
Outcome indicators: C-reactive protein (CRP); superoxide dismutase (SOD) levels; malondialdehyde (MDA) levels; vascular endothelial growth factor (VEGF) levels; endothelin-1 (ET-1) levels; nitric oxide (NO) levels; cerebral infarct volume CIV; cerebral infarct size (CIS); and Adverse reaction ratio.
Publication 2023
Cerebral Infarction Cerebrovascular Accident Chinese C Reactive Protein Diagnosis Endothelin-1 Gender Malondialdehyde Oxide, Nitric Patients Pharmaceutical Preparations Stroke Volume Superoxide Dismutase Thrombolytic Therapy Vascular Endothelial Growth Factors
Study materials were collected from the Suzhou Taicang Hospital of Traditional Chinese Medicine from November 2020 to August 2022. There were 178 cases where a diagnosis of AIS was made. The ethics committee of the Suzhou Taicang Hospital of Traditional Chinese Medicine approved this study and waived patient consent due to the retrospective study design (Grant No. 2022-023). All study procedures were carried out in accordance with the relevant guidelines and regulations.
Among these 178 cases, 57 patients who met the following criteria at our institution were retrospectively included in this study: (1) all patients clinically diagnosed with AIS had undergone one-stop, plain CT scan, CTP, and CTA, (2) all scans were performed within the 24 h of the onset of AIS, (3) all data had undergone valid quantitative analysis by F-STROKE (16 (link)), an automated perfusion analysis software (version 1.0.18; Neuroblast, Ltd. Co.), (4) all diagnostic images were clear, with no obvious motion artifacts or metallic artifacts evident, (5) no other brain diseases, such as brain tumors, vascular malformations, or cerebral hemorrhages, and (6) no previous history of thrombolytic therapy or massive cerebral infarction. Exclusion criteria included (1) the time of onset was >24 h, (2) the quantitative value was too small (ischaemic focus range: <5 mL), as determined using the F-STROKE software, (3) a history of thrombolytic therapy or massive cerebral infarction, (4) brain tumor or cerebrovascular disease, or (5) CT image quality did not meet the evaluation requirements (e.g., based on the presence of titanium clip artifacts or heavy motion artifacts). A flow chart of the inclusion/exclusion process is displayed in Figure 1. The CTA showed corresponding stenosis or occlusion in 50 cases and was normal in 7 cases.
Publication 2023
Brain Diseases Brain Neoplasms Cerebral Hemorrhage Cerebral Infarction Cerebrovascular Accident Cerebrovascular Disorders Clip Dental Occlusion Diagnosis Ethics Committees, Clinical Metals Patients Perfusion Radionuclide Imaging Stenosis Thrombolytic Therapy Titanium Vascular Malformations X-Ray Computed Tomography
We retrospectively reviewed the data of 211 patients with PBSH from 342 consecutive patients admitted to our institution between January 2014 and October 2020. The inclusion criteria were as follows: (1) a diagnosis of PBSH confirmed by CT and (2) complete clinical data (laboratory data, imaging data, and other clinical data). The exclusion criteria were as follows: (1) secondary brainstem hemorrhage caused by trauma, thrombolytic therapy, cavernous hemangioma, or arteriovenous malformation, (2) surgical treatment of brainstem hemorrhage before admission to our hospital, (3) admission to our hospital more than 10 days after symptom onset, and (4) missed follow-up.
Publication 2023
Arteriovenous Malformation Brain Stem Diagnosis Hemangioma, Cavernous Hemorrhage Operative Surgical Procedures Patients Surgical Blood Losses Thrombolytic Therapy Wounds and Injuries
The diagnosis criteria for AMI were based on the 2012 ESC/AHA/ACC guidelines.17 (link) Specific details are as follows: (a) the cTn level should be 99% higher than the upper limit reference value; (b) significant changes in the ST-T stage or left bundle branch block; (c) obvious symptoms of ischemia in electrocardiogram; (d) coronary thrombosis in angiography; and (e) loss of viable heart muscle or abnormal ventricular wall. Patients who had received anticoagulation or thrombolytic therapy and patients with other comorbidities or organ failures were excluded. Healthy individuals without a history of cardiovascular diseases and thrombolytics were included.
According to the above criteria, a total of 83 AMI patients and 62 healthy individuals were included in this study from June 2019 to June 2020. Approval was obtained from the ethics committee of Beijing JiShuiTan Hospital. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. All participants had signed the informed consent. The AMI patients were followed up for 6 months after corresponding treatments. The cardiovascular events and all cause-induced deaths were defined as the endpoints.
Publication 2023
Angiography Cardiovascular Diseases Cardiovascular System Coronary Angiography Coronary Thrombosis Diagnosis Electrocardiography Ethics Committees, Clinical Fibrinolytic Agents Heart Ventricle Ischemia Left Bundle-Branch Block Myocardium Patients Thrombolytic Therapy Thrombosis
We enrolled 930 ischemic stroke patients with thrombolytic therapy within 6 h of the stroke onset from July 2018 to June 2020 retrospectively in two stroke centers in the local hospital, whose age ranged from 18 to 80 years and head computed tomography (CT) scans showed no acute hemorrhage. Twelve patients with missing clinical data were excluded. For stroke patients with an onset within 4.5 h, rtPA was directly delivered, and for patients whose onset was 4.5–6 h, rtPA was not given until magnetic resonance imaging (MRI) showing new infarction area. The comprehensive treatments for these patients in two centers were consistent and based on both European stroke organizations (ESO) guidelines on intravenous thrombolysis (Berge et al., 2021 (link)) and Chinese guidelines.
The mRs system was used to evaluate the neurological outcome at 3 months after the thrombolysis for these patients, and mRs < 2 was considered as a favorable neurological outcome, while mRs 2–6 was poor outcome. This study was approved by the Ethical Board of Shanghai Pudong New Area People’s Hospital with a waiver of informed consent due to the retrospective nature of the study. Informed consent for intravenous thrombolysis was obtained from all patients.
Publication 2023
Alteplase Cerebrovascular Accident Chinese Europeans Fibrinolytic Agents Head Hemorrhage Infarction Patients Radionuclide Imaging Stroke, Ischemic Thrombolytic Therapy X-Ray Computed Tomography

Top products related to «Thrombolytic Therapy»

Sourced in Germany, France
Actilyse is a laboratory equipment product manufactured by Boehringer Ingelheim. It is a recombinant tissue plasminogen activator (rt-PA) used for the in vitro analysis of fibrinolytic systems.
Sourced in Germany
Rt-PA is a laboratory equipment product used in research applications. It is a recombinant tissue plasminogen activator, a protein that plays a role in the breakdown of blood clots. The core function of Rt-PA is to facilitate the conversion of plasminogen to plasmin, which is an enzyme involved in the dissolution of fibrin clots.
Sourced in Germany
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It functions to dissolve blood clots by activating plasminogen, which then converts fibrin into soluble fragments.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Germany, United Kingdom, Canada, Macao, Japan, France, Switzerland, Hungary, Italy, China
Fibrinogen is a plasma protein that plays a crucial role in the blood clotting process. It is a component of the coagulation cascade and is essential for the formation of fibrin clots.
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Italy, Switzerland, Australia, Sweden, Belgium, New Zealand, Denmark, Mexico, Jersey, South Sudan, Austria, Japan
The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Switzerland, Sweden, Ireland, Macao, India, Australia, France, Spain
Thrombin is a serine protease enzyme that plays a crucial role in the blood coagulation process. It is responsible for the conversion of fibrinogen to fibrin, which is the main structural component of blood clots. Thrombin also activates other factors involved in the clotting cascade, promoting the formation and stabilization of blood clots.
Sourced in Germany, United States, China, Japan
The Genomic DNA purification kit is a laboratory tool designed to extract and purify high-quality genomic DNA from a variety of biological samples. The kit employs a standardized process to efficiently isolate DNA, making it suitable for downstream applications such as PCR, sequencing, and other molecular biology techniques.
Sourced in Japan
The SH-1000Lab is a piece of laboratory equipment used for the measurement and analysis of various samples. It is designed to perform specific functions within a controlled laboratory environment.

More about "Thrombolytic Therapy"

Thrombolytic Therapy, also known as fibrinolytic therapy or clot-busting treatment, is a medical intervention that utilizes pharmacological agents to dissolve or break up blood clots (thrombi) within the body.
This treatment approach is commonly used in the management of conditions such as acute myocardial infarction (heart attack), ischemic stroke, and deep vein thrombosis.
The goal of Thrombolytic Therapy is to restore blood flow and prevent further tissue damage caused by the obstructed blood vessel.
This is typically achieved through the use of thrombolytic agents like Actilyse (alteplase, recombinant tissue plasminogen activator or rt-PA), which work by activating the body's natural fibrinolytic system to break down the fibrin in the clot.
Effective protocols for this therapy are crucial for ensuring optimal outcomes and reproducibility in clinical research and practice.
Researchers may utilize tools like SAS 9.4 and Prism 9 to analyze data and develop the most effective Thrombolytic Therapy solutions.
In addition to pharmacological agents, Thrombolytic Therapy may also involve the use of laboratory tests and equipment, such as BD Vacutainer blood collection systems, genomic DNA purification kits, and coagulation assays to measure fibrinogen and thrombin levels.
Careful monitoring and adjustment of these parameters can help ensure the safety and efficacy of the treatment.
By leveraging the power of AI-driven comparison tools like PubCompare.ai, researchers can discover the optimal research protocols for Thrombolytic Therapy, locating and identifying the best protocols across literature, pre-prints, and patents.
This helps to ensure reproducibility and accuracy in their research, ultimately leading to improved patient outcomes.